lorcainide lorcainide hydrochloride class antiarrhythmic agent used help restore normal heart rhythm conduction patients premature ventricular contractions ventricular lorcainide developed janssen pharmaceutica belgium commercial name remivox designated code numbers ro halflife hrs may prolonged hrs people cardiac cardiac dysrhythmia heart rate disorder manifests altered cardiac rhythm results either abnormal pacemaker activity disturbance impulse propagation arrhythmias caused various conditions including ischemia hypoxia ph disruptions b adrenergic activation drug interactions presence diseased events trigger development ectopic pacemaker heart emit abnormal impulses random times cardiac cycle arrhythmia present either bradycardia untreated arrhythmias may progress atrial fibrillation ventricular treatment aimed normalizing cardiac rhythm altering ion flow across membrane antiarrhythmic agents reduce arrhythmia related symptoms palpitations syncope however often narrow therapeutic index also syndrome wpw preexcitation syndrome individuals predisposed supraventricular tachyarrhythmias rapid irregular heart people condition extra accessory atrioventricular conduction pathway causes reentry wpw characterized short pr interval fastacting voltagegated sodium channels found high concentrations ventricular myocytes open membrane potential mv typical cardiac rhythm result rapid upstroke action potential leads contraction class drugs local anesthetic properties high affinity open closed inactive thus irreversibly binding reducing fast na influx interactions lorcainide time voltage dependent class drugs characteristically slow dissociation rate slow upstroke duration amplitude ventricular myocytes action potential prolong pr qrs qt intervals lorcainide also increases ventricular fibrillation threshold dosedependent overall lorcainide causes decrease tachycardiac events also reduced ventricular contractility ejection fraction effect sinus node function controversial researchers noted decreased sinus cycle length increase sinus node recovery whereas others observed lorcainide inhibits adenosine triphosphate atphydrolytic action myocardial nakatpase invitro concentration dependent manner mode action implications finding well lorcainide exhibits prolonged duration action approximately hrs well absorbed taken orally good safety profile well good drug hematologic biochemical urinary analysis lorcainide revealed significant however increased prevalence central nervous system effects including headache dizziness sleep disturbances associated oral dosages lorcainide compared intravenous administration could due greater accumulation plasma noriorcainide exposed oral lorcainide noriorcainide ndealkylated derivative active metabolite lorcainide potent parent compound similar antiarrhythmic efficacy wherein suppresses chronic premature ventricular half life synthesis starts reducing anil formed condensation pchloroaniline sodium borohydride acylated phenacetyl chloride produce amide selective hydrolysis hydrobromic acid hbr followed alkylation isopropyl bromide completes synthesis lorcainide httpsenwikipediaorgwikilorcainide